Your shopping cart is currently empty

7-BIA is a receptor-type protein tyrosine phosphatase D (PTPRD) inhibitor with anti-addictive properties, and is utilized in neuropathic pain research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $148 | In Stock | In Stock | |
| 5 mg | $372 | In Stock | In Stock | |
| 10 mg | $645 | In Stock | In Stock | |
| 25 mg | $1,190 | In Stock | In Stock | |
| 50 mg | $1,880 | - | In Stock | |
| 100 mg | $2,980 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $397 | In Stock | In Stock |
| Description | 7-BIA is a receptor-type protein tyrosine phosphatase D (PTPRD) inhibitor with anti-addictive properties, and is utilized in neuropathic pain research. |
| Targets&IC50 | PTPRS:40 μM (Human), PTPRD:1-3 μM (Human) |
| In vitro | 7-BIA inhibits recombinant human PTPRD and recombinant human PTPRS with IC50 values of approximately 1-3 μM and 40 μM, respectively[1]. |
| In vivo | Administered via intraperitoneal injection at a single dose of 10-20 mg/kg, 7-BIA reduces cocaine self-administration in experienced wild-type mice[1]. |
| Animal Research | Animal Model: WT mice (available cocaine 50 times, 1 mg/kg infusions on FR1 schedule during ≥20 prior sessions). Dosage: 10 mg/kg, 20 mg/kg. Administration: Given i.p.; only once |
| Molecular Weight | 294.3 |
| Formula | C15H18O6 |
| Cas No. | 1313403-49-4 |
| Smiles | CCCCOc1cc2C(=O)OC(O)Cc2c(C=O)c1OC |
| Relative Density. | 1.279 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (271.83 mM), Sonication is recommended. Ethanol: 30 mg/mL (101.94 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (16.99 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.